StimCardio Medical, a Los Angeles-based medical device company developing wearable therapies for atrial fibrillation, has raised $30 million in an oversubscribed Series A financing round led by Metis MedTech, the investment platform founded by medical technology entrepreneur John Slump.
The round also included participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors.
Founded in 2015 as CardiaCare by Amos Ziv, who was later joined by co-founder Tsahi Holand, the company develops non-invasive neuromodulation technologies for cardiac rhythm disorders. It currently operates as StimCardio Medical under the leadership of CEO Amir Soltanianzadeh.
StimCardio’s lead investigational product, Rhyvive, is a wrist-worn device designed to deliver personalized median nerve stimulation. The system combines physiological sensing with closed-loop neuromodulation and is being developed to complement catheter ablation, a procedure used to treat atrial fibrillation.
The wearable is intended for use outside clinical settings, allowing patients to receive non-invasive stimulation at home with the goal of reducing recurrent atrial arrhythmias following ablation. The device remains investigational and has not received regulatory clearance or approval.
StimCardio plans to direct the new capital toward its NeuroPulse 2 pivotal clinical study, which will evaluate whether adding wearable neuromodulation to catheter ablation improves clinical outcomes compared with ablation alone. The financing will also support preparations for a De Novo submission to the US Food and Drug Administration.
The funding follows results from the NeuroPulse pilot study, published in the peer-reviewed journal Heart Rhythm in September 2026. The randomized, double-blind, sham-controlled study enrolled 77 patients and reported fewer recurrent atrial arrhythmia events among patients receiving active median nerve stimulation. The researchers concluded that the findings require confirmation in a larger trial.
The company previously completed a seed-extension financing round in September 2023, when it operated as CardiaCare. That investment was led by Solardis Health Ventures and supported the expansion of its clinical research programme.
